How TP-05's Phase 2 Lyme Prophylaxis Trial Progress Could Impact Tarsus Pharmaceuticals (TARS) Investors [Yahoo! Finance]
Tarsus Pharmaceuticals, Inc. (TARS)
Company Research
Source: Yahoo! Finance
This program targets a large unmet need as a potential first-in-class, non-vaccine, drug-based prophylactic for Lyme disease, where no FDA-approved preventive drugs currently exist. We'll now examine how TP-05's Phase 2 progress, building on earlier “tick kill” data, could influence Tarsus Pharmaceuticals' broader investment narrative. Find 62 companies with promising cash flow potential yet trading below their fair value Tarsus Pharmaceuticals Investment Narrative Recap To own Tarsus, you need to believe XDEMVY can keep driving the business while the pipeline adds meaningful, differentiated products over time. In the near term, XDEMVY adoption and margins still look like the main catalyst and risk, respectively, and the TP 05 Calliope Phase 2 start does not materially change that focus yet, even though it opens an intriguing longer term opportunity in Lyme disease prevention. The recent US$15,000,000 milestone tied to TP 03 approval in China is more directly relevant to to
Show less
Read more
Impact Snapshot
Event Time:
TARS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TARS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TARS alerts
High impacting Tarsus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
TARS
News
- Tarsus Pharmaceuticals: Marketing Spend Bears Fruit, Pipeline Progresses [Seeking Alpha]Seeking Alpha
- Tarsus Pharmaceuticals (TARS) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TARS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hMarketBeat
- Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme DiseaseGlobeNewswire
- Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade [Yahoo! Finance]Yahoo! Finance
- TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus [Yahoo! Finance]Yahoo! Finance
TARS
Earnings
- 2/23/26 - Miss
TARS
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/24/26 - Form 4
- 3/20/26 - Form 144
- TARS's page on the SEC website